RCMI Coordinating Center (RCMI CC) Header Logo

EMP2 is a novel therapeutic target for endometrial cancer stem cells.

Kiyohara MH, Dillard C, Tsui J, Kim SR, Lu J, Sachdev D, Goodglick L, Tong M, Torous VF, Aryasomayajula C, Wang W, Najafzadeh P, Gordon LK, Braun J, McDermott S, Wicha MS, Wadehra M. EMP2 is a novel therapeutic target for endometrial cancer stem cells. Oncogene. 2017 10 19; 36(42):5793-5807.

View in: PubMed

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support